Dr. Mojtaba Noofeli, Director of the Razi Cov Pars vaccine clinical trial site highlighted that the Razi vaccine platform is a recombinant protein, its effectiveness on other strains has been determined and can be effective in the face of the new omicron strain. Studies led by WHO are currently underway on the effectiveness of existing vaccines against the new Omicron strain, but the final results have not yet been published. In order to perform the neutralization test and the antibody-induced function of the vaccine on the new strain, it is first necessary to isolate and culture the virus and provide it for testing, which has not been officially isolated in Iran at present, he added.

Dr. Noofeli clarified about the injection of Razi vaccine as a booster dose and point out that a study is currently underway and the results of which will be officially announced next week. In the study, Razi vaccine is injected as a booster dose of Astrazenka, Sputnik, Sinofarm, Barakat vaccines and Razi Cov Pars vaccine itself, which is very safe in terms of harmlessness and has good antibody titers. The Director of Razi Cov Pars vaccine clinical trial site added, "the clinical study of Razi Cov Pars vaccine for the age group of 12 to 18 years has received a clinical study license, which will start next week." He pointed out that the clinical study phase of people aged 12 to 18 will be completed in a few weeks, as we have a good reception from the participants of this age group. Due to the young ages of these people, we can see a good immune response by injecting two doses of the vaccine, but if necessary, and examining this age group, we can also consider the intranasal dose. Although in this group as well as in older age groups, injecting two doses of vaccine is sufficient for effective immunity, but in order to interrupt the virus transmission cycle in pandemic conditions, using an intranasal dose will be very effective.

Dr. Noofli underlined that 5 million doses of vaccine are ready for delivery, which we can be delivered as soon as possible, according to the needs of the country and the request of the Ministry of Health. Fortunately, due to the excellent results of this vaccine in the pre-clinical and clinical study phases I,II and III, there are now inquiries from some countries for the export of Razi Cov Pars vaccine, and negotiations are underway in this regard.

http://en.areeo.ac.ir/news/safety-of-razi-cov-pars-vaccine-against-omicron